Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marek Pruszynski

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Nuclear Medicine and Biology|July 7, 2017
<sup>211</sup>At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatmentMonika Lyczko, Marek Pruszynski, Agnieszka Majkowska-Pilip, et al.
EJNMMI Radiopharmacy and Chemistry|April 4, 2025
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with <sup>225</sup>AcKateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
<sup>131</sup>I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer TreatmentMatthias D'Huyvetter, Jens De Vos, Catarina Xavier, et al.
Molecular Cancer Therapeutics|October 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide TherapyJanik Puttemans, Benoit Stijlemans, Marleen Keyaerts, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Nuclear Medicine and Biology|July 7, 2017
<sup>211</sup>At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatmentMonika Lyczko, Marek Pruszynski, Agnieszka Majkowska-Pilip, et al.
EJNMMI Radiopharmacy and Chemistry|April 4, 2025
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with <sup>225</sup>AcKateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
<sup>131</sup>I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer TreatmentMatthias D'Huyvetter, Jens De Vos, Catarina Xavier, et al.
Molecular Cancer Therapeutics|October 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide TherapyJanik Puttemans, Benoit Stijlemans, Marleen Keyaerts, et al.
Pageof 2